首頁
HAS Healthcare Advanced Synthesis SA

7月 2026HAS Healthcare Advanced ...的市場佔有率分析

HAS Healthcare Advanced Synthesis SA is delighted to announce a significant milestone in its journey – its 40th anniversary! For four decades, HAS Healthcare Advanced Synthesis has stood as a beacon of excellence in the international chemical-pharmaceutical industry, providing unparalleled services in pharmaceutical development and manufacturing.

行業: N/A

域名hashealthcare.com

成立年份1984

僱員51 - 200

年度營收$75M - $100M

HAS Healthcare Advanced Synthesis SA

HAS Healthcare Advanced Synthesis SA（包含公司地區）

hashealthcare.com

查看更多網站流量與參與度資訊

HAS Healthcare Advanced Synthesis SA截至 7月 2026 的總收入為 75M - 100M

HAS Healthcare Advanced Synthesis SA 熱門網域產生的總收入

HAS Healthcare Advanced Synthesis SA 熱門網域 3 年內的總收入

HAS Healthcare Advanced Synthesis SA 熱門網域的總收入

hashealthcare.com75M - 100M

透過銷售情報查看更多內容

HAS Healthcare Advanced Synthesis SA的熱門網域總造訪量

了解HAS Healthcare Advanced Synthesis SA市場觸達率與潛在市場影響力。

過去 3 個月的訪問總量

子公司細目

hashealthcare.com1.8K

透過銷售情報查看更多內容

HAS Healthcare Advanced Synthesis SA的熱門網域平均造訪時長

分析HAS Healthcare Advanced Synthesis SA參與度指標。

過去 3 個月平均造訪時長

子公司細目

hashealthcare.com00:00:05

透過銷售情報查看更多內容

HAS Healthcare Advanced Synthesis SA的熱門網域平均頁面瀏覽量

了解HAS Healthcare Advanced Synthesis SA如何保持使用者的參與度、培養其興趣，並鼓勵他們採取下一步。

過去 3 個月平均頁面瀏覽量

子公司細目

hashealthcare.com1.86

透過銷售情報查看更多內容

HAS Healthcare Advanced Synthesis SA按網域劃分的熱門競爭對手

看起來這裡的數據不足

無可顯示數據

使用的熱門技術HAS Healthcare Advanced Synthesis SA

这些是HAS Healthcare Advanced Synthesis SA顶级域名使用的行业网站技术

付費廣告 (3)

DoubleClick

電子郵件服務 (2)

Microsoft Exchange Online

市場行銷 (2)

Google Marketing Platform

行動裝置 (2)

Meta Viewport

更多技術

6

檢視所有

新聞與訊號來自HAS Healthcare Advanced Synthesis SA

透過 Similarweb 銷售訊號提醒，每當目標受眾出現新的機會或威脅時，你就會收到每日更新的已識別購買訊號。

新聞HAS Healthcare Advanced Synthesis SA partnered with Biodelphis Therapeutics on Jan 1st '26.This collaboration combines HAS Group long-standing expertise in complex bioconjugation, process development, and clinical-grade manufacturing with Biodelphis Therapeutics' pioneering APIC platform, a novel drug modality engineered to deliver highly selective protease inhibition directly to diseased tissues.

新聞HAS Healthcare Advanced Synthesis SA acquired Cerbios-Pharma SA on Mar 1st '25.On the mergers and acquisitions front, HAS Healthcare Advanced Synthesis SA acquired Cerbios-Pharma SA in March 2025, expanding its CDMO capabilities to include biologics and hybrid drug substances.